Volume: 11 Issue: 2
Year: 2023, Page: 17-22, Doi: https://doi.org/10.47799/pimr.1102.04
Received: March 27, 2023 Accepted: July 30, 2023 Published: July 30, 2023
Introduction: Evaluation of the patients who present to the hospital with a complaint of chest pain or other signs suggestive of acute coronary syndrome (ACS) is time-consuming, expensive, and difficult. Most of the biochemical markers are negative in early phase acute myocardial ischemia. Recent literature reports have shown more interest in a new biochemical marker which is Ischemia-modified albumin for the detection of myocardial injury. Objective: to estimate the level of ischemia-modified albumin (IMA) as a risk factor for cardiovascular disease in diabetes mellitus patients.
Materials and methods: A case-control study was undertaken with sixty Type-2 diabetic patients as cases and sixty non-diabetic healthy subjects as controls. Demographic data (sex, age), an ECG and Biochemical data were collected. Blood for IMA and HbA1C levels was collected within two hours of arrival, and IMA risk marker testing was performed before any heparin/thrombolytic treatment was started. Controlled and uncontrolled diabetic patients were determined by the level of their HBA1c and comparison with the means of IMA level in their serum.
Results: The IMA was significantly increased in diabetic patients compared to healthy controls, with cut off value (0.92 IU/L), and there is also a significant increase in IMA level in uncontrolled diabetic patients (Mean ± SD; 240.55 + 52.5) that presented with acute chest pain and have signs and symptoms of cardiac ischemia when compared with the well-controlled diabetic patients(Mean ± SD; 159.8 ± 60.4).
Conclusion: Ischemic Modified Albumin (IMA) level was elevated significantly in uncontrolled diabetic patients with early signs of early myocardial ischemia. Additionally, IMA estimation may improve our ability to identify ischaemic patients who are missed by current diagnostic strategies, or more confidently rule out patients who do not have ACS.
Keywords: acute coronary syndrome (ACS), ischemia-modified albumin (IMA), Biomarker, Diabetes Mellitus
Shaoqing, J, Juan, N & Jianyou, S . 2008. Ischemia-Modified albumin is Increased in Patients with Unstable Angina: A new Potential Diagnostic biomarker of this Acute Coronary Syndrome. Lab Med 39(11):668–70.
Piwowar, A, Knapik-Kordecka, M & Warwas, M . 2008. Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report. Dis Markers 24(6):311–318.
Lee, Y W, Kim, H J, Cho, Y H, Shin, H B, Choi, T Y & Lee, Y K . 2007. Application of albumin-adjusted ischemia modified albumin index as an early screening marker for acute coronary syndrome. PMID 17570353 384:24–31.
Lippi, G, Montagnana, M & Salvagno, G L . 2006. Potential value for new diagnostic markers in the early recognition of acute coronary syndromes. CJEM 8(1):27–31.
Peacock, F, Morris, D L, Anwaruddin, S, Christenson, R H, Collinson, P O & Goodacre, S W . 2006. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. PMID 16875905 152:253–62.
Apple, F S, Wu, A H, Mair, J, Ravkilde, J, Panteghini, M & Tate, J . 2005. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. PMID 15774573 51:810–834.
Sinha, M K, Roy, D, Gaze, D C, Collinson, P O & Kaski, J C . 2004. Role of ”ischemia modified albumin”, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 21(1):29–34.
Christenson, R H, Duh, S H, Sanhai, W R, Wu, A H, Holtman, V & Painter, P . 2001. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: A muticenter study. Clin Chem 47(3):464–70.
Adams, J & Apple, F . 2004. Cardiology patient page. New blood tests for detecting heart disease. Circulation 109(3):14744959.
Kanko, M, Yavuz, S, Duman, C, Hosten, T, Oner, E & Berki, T . 2012. Ischemia-modified albumin use as a prognostic factor in coronary bypass surgery. J Cardiothorac Surg 7(3):3.
Bar-Or, D, Lau, E & Winkler, J V . 2000. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 19(4):311–316.
Borderie, D, Allanore, Y, Meune, C, Devaux, J Y, Ekindjian, O G & Kahan, A . 2004. High ischemia- modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem 50(11):2190–2193.
Montagnana, M, Lippi, G, Volpe, A, Salvagno, G L, Biasi, D & Caramaschi, P . 2006. Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 39(9):913–920.
Refaai, M A, Wright, R W, Parvin, C A, Gronowski, A M, Scott, M G & Eby, C S . 2006. Ischemia- modified albumin increases after skeletal muscle ischemia during arthroscopic knee surgery. Clin Chim Acta 366(1-2):264–272.
Montagnana, M, Lippi, G, Fava, C, Minuz, P, Santonastaso, C L & Arosio, E . 2006. Ischemia-modified albumin and NT-prohormone- brain natriuretic peptide in peripheral arterial disease. Clin Chem Lab Med 44(2):16475909.
Laver, Stephen R & Padkin, Andrew . 2005. Does hyperglycaemia precede the clinical onset of myocardial ischaemia? Resuscitation 66(2):237–239.
Sadik, I, Yagoub, Z & Sayed, N . 2017. The level of ischemic modified albumin (IMA) as risk marker for cardio vascular disease among some diabetic patients (type II) in Khartoum state- Sudan. Sudan J Med Sci 12(4):231–240.
Ukinc, K, Eminagaoglu, S, Ersoz, H O, Erem, C, Karahan, C & Hacihasanoglu, A B . 2009. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine 36(3):425–457.
Kumar, A, Sivakanesan, R & Singh, S . 2008. Oxidative stress, endogenous antioxidant and ischemia- modified albumin in normolipidemic acute myocardial infarction patients. J Health Sci 54(4):482–489.
Bar-Or, D, Curtis, G, Rao, N, Bampos, N & Lau, E . 2001. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 268(1):42–49.
Roy, D, Quiles, J, Gaze, D C, Collinson, P, Kaski, J C & Baxter, G F . 2006. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 92(1):113–117.
Defronzo, R A . 1997. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5(3):177–269.
Panimathi, R & Lalitha, . 2016. Ischemia modified albumin -An early marker of myocardial ischemia. JMSCR 4(7):11596–604.
Junedi MA, Junaidi AA. Ischemia-Modified Albumin (IMA) for early detection of myocardial ischemia in acute coronary syndrome with type 2 diabetes mellitus: a case control study. Perspectives in Medical Research. 2023;11(2):17-22 DOI: 10.47799/pimr.1102.04